Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Huhn

Showing results (111-120 of 138) with videos related to

Pageof 14
Sort By:
Pain|March 4, 2025
A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain modelCecilia L Bergeria, Chung Jung Mun, Traci J Speed, et al.
Pain|August 21, 2025
A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain modelCecilia L Bergeria, Chung Jung Mun, Traci J Speed, et al.
Psychoneuroendocrinology|August 14, 2025
Effects of suvorexant on diurnal cortisol and patient-reported stress during opioid withdrawal in a randomized trialGreer McKendrick, Charlotte Clapham, Vadim Zipunnikov, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 18, 2023
Within-subject, double-blind, randomized, placebo-controlled evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic painClaudia M Campbell, Chung Jung Mun, Katrina R Hamilton, et al.
Science Translational Medicine|June 22, 2022
Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taperAndrew S Huhn, Patrick H Finan, Charlene E Gamaldo, et al.
Neurology|November 28, 2001
The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's typeG D Silverberg, G Heit, S Huhn, et al.
Drug and Alcohol Dependence|July 3, 2021
Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphoneGabrielle Agin-Liebes, Andrew S Huhn, Eric C Strain, et al.
Journal of Addiction Medicine|December 17, 2025
Performance of Xylazine Qualitative Immunoassays Designed for Drug Checking in Urine SamplesEmma Pattillo, Yi Xie, Aicha Monteiro, et al.
Addiction Biology|January 15, 2024
Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype-genotype assessmentKelly E Dunn, Andrew S Huhn, Patrick H Finan, et al.
Anesthesiology|January 2, 2026
Evaluating the Acute Effects of the Cannabinoid Dronabinol and the Opioid Hydromorphone Alone and in Combination: A Double-Blind, Randomized, Placebo-Controlled Trial in Knee OsteoarthritisKatrina R Hamilton, Chung Jung Mun, Eliot Sadik, et al.
Pageof 14

Showing results (111-120 of 138) with videos related to

Sort By:
Pageof 14
Pain|March 4, 2025
A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain modelCecilia L Bergeria, Chung Jung Mun, Traci J Speed, et al.
Pain|August 21, 2025
A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain modelCecilia L Bergeria, Chung Jung Mun, Traci J Speed, et al.
Psychoneuroendocrinology|August 14, 2025
Effects of suvorexant on diurnal cortisol and patient-reported stress during opioid withdrawal in a randomized trialGreer McKendrick, Charlotte Clapham, Vadim Zipunnikov, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 18, 2023
Within-subject, double-blind, randomized, placebo-controlled evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic painClaudia M Campbell, Chung Jung Mun, Katrina R Hamilton, et al.
Science Translational Medicine|June 22, 2022
Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taperAndrew S Huhn, Patrick H Finan, Charlene E Gamaldo, et al.
Neurology|November 28, 2001
The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's typeG D Silverberg, G Heit, S Huhn, et al.
Drug and Alcohol Dependence|July 3, 2021
Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphoneGabrielle Agin-Liebes, Andrew S Huhn, Eric C Strain, et al.
Journal of Addiction Medicine|December 17, 2025
Performance of Xylazine Qualitative Immunoassays Designed for Drug Checking in Urine SamplesEmma Pattillo, Yi Xie, Aicha Monteiro, et al.
Addiction Biology|January 15, 2024
Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype-genotype assessmentKelly E Dunn, Andrew S Huhn, Patrick H Finan, et al.
Anesthesiology|January 2, 2026
Evaluating the Acute Effects of the Cannabinoid Dronabinol and the Opioid Hydromorphone Alone and in Combination: A Double-Blind, Randomized, Placebo-Controlled Trial in Knee OsteoarthritisKatrina R Hamilton, Chung Jung Mun, Eliot Sadik, et al.
Pageof 14